BIEL Stock Overview
BioElectronics Corporation, an electroceutical company, engages in the development and sale of wearable, neuromodulation devices to mitigate neurological diseases and enhance quality of life worldwide.
BioElectronics Corporation Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.0008|
|52 Week High||US$0.0025|
|52 Week Low||US$0.0005|
|1 Month Change||-15.79%|
|3 Month Change||33.33%|
|1 Year Change||-66.67%|
|3 Year Change||-11.11%|
|5 Year Change||14.29%|
|Change since IPO||-99.83%|
Recent News & Updates
|BIEL||US Medical Equipment||US Market|
Return vs Industry: BIEL underperformed the US Medical Equipment industry which returned -20.7% over the past year.
Return vs Market: BIEL underperformed the US Market which returned -8.9% over the past year.
|BIEL Average Weekly Movement||23.2%|
|Medical Equipment Industry Average Movement||9.4%|
|Market Average Movement||7.6%|
|10% most volatile stocks in US Market||17.0%|
|10% least volatile stocks in US Market||3.1%|
Stable Share Price: BIEL is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 23% a week.
Volatility Over Time: BIEL's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
BioElectronics Corporation, an electroceutical company, engages in the development and sale of wearable, neuromodulation devices to mitigate neurological diseases and enhance quality of life worldwide. Its products include ActiPatch, a musculoskeletal pain therapy; Allay, a menstrual pain therapy; and Smart Insole, a heel pain therapy. The company also offers RecoveryRx, a medical device that provides pain management therapy for medical professionals; and HealFast, a drug-free therapy for horses, cats, and dogs that reduces swelling and pain, as well as heals muscle and tendon injuries, sores, and incisions.
BioElectronics Corporation Fundamentals Summary
|BIEL fundamental statistics|
Is BIEL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BIEL income statement (TTM)|
|Cost of Revenue||US$813.93k|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.00001|
|Net Profit Margin||-18.01%|
How did BIEL perform over the long term?See historical performance and comparison